Rohit Loomba
University of California San Diego
Appearances
DateMay 19, 2024BACKGROUND AND AIMS: There is conflicting data on the risk of fibrosis and liver-related outcomes in patients with lean MASLD and the role of genetic testing in this population…Presenter
Speakers
- DateMay 19, 2024INTRODUCTION. MAESTRO-NASH (NCT03900429) is an ongoing 54-month, randomized, double-blind, placebo-controlled Phase 3 trial evaluating the efficacy of resmetirom in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and fibrosis…
Presenter
University of California San Diego - DateMay 18, 2024
Presenter
University of California San Diego - DateMay 18, 2024
Presenters
University of California San DiegoUniversity of Wisconsin-Madison - DateMay 19, 2024
Presenters
University of Wisconsin-MadisonUniversity of California San Diego 
DateMay 19, 2024SOCIETY: AASLDModerators
Mayo ClinicUniversity of California San Diego- DateMay 20, 2024BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form metabolic dysfunction-associated steatohepatitis (MASH) are highly prevalent worldwide. However, current non-invasive diagnostic approaches for MASLD and MASH are suboptimal…
Presenter
Speakers
University of California San Diego - DateMay 19, 2024
Presenters
